Fullerene Radiopharmaceuticals

  • G. J. Ehrhardt
  • L. J. Wilson
Chapter
Part of the Developments in Fullerene Science book series (DFUL, volume 1)

Abstract

Radiopharmaceuticals are radioactively tagged compounds used primarily to diagnose disease in humans. They allow the imaging of physiologic or disease-state processes with an external gamma ray camera, typically using a simple, two-dimensional Anger camera, a single photon emission computed tomograph (SPECT instrument), or a positron emission tomograph (PET instrument). Short-lived isotopes give little radiation dose and are greatly preferred for these purposes. The mainstay of diagnostic nuclear medicine is the 99Mo/99mTc generator, which is used to produce 99mTc sodium pertechnetate conveniently and in high purity for formulation of radiopharmaceuticals. Common 99mTc agents include those for imaging bone cancer (99mTc methylene diphosphonate, or MDP), radioaerosols of 99mTc for examining lung ventilation (Technegas), 99mTc Cardiolite™ for assessing coronary artery blockages, and 99mTc Miraluma™ for diagnosing breast cancer. The common theme with these agents is the use of carrier molecules to direct a short-lived bound radioactive isotope through a physiological process to permit the process’ observation.

Keywords

Single Photon Emission Compute Tomograph High Specific Activity Positron Emission Tomograph Fullerene Cage Neutron Bombardment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Burch, W.M., Sullivan, P.J., McLaren, C.J.: Nucl. Med. Commun., 7 (1986) 865–871.CrossRefGoogle Scholar
  2. [2]
    Scalzetti, E.M., Gagne, G.M.: J. Nucl. Med., 36 (1995) 267–269.Google Scholar
  3. [3]
    Mackey, D.W., Burch, W.M., Dance, J.G., Fisher, K.J., Willett, G.D.: Nucl. Med. Commun., 6 (1994) 430–434.CrossRefGoogle Scholar
  4. [4]
    Burch, W.M., Browitt, R.J.: J. Nucl. Med, 10 (1996) 1917–1918.Google Scholar
  5. [5]
    Senden, T.J., Moock, K.H., Gerald, J.F., Burch, W.M., Browitt, R.J., Ling, CD.: J. Nucl. Med, 8 (1997) 1327–1333.Google Scholar
  6. [6]
    Jackson, P., Mackey, D., Van der Wall, H.:. J. Nucl. Med, 9 (1998) 1646–1649.Google Scholar
  7. [7]
    Koch, A.S., Khemani, K.C., Wudl, F.: J. Org. Chem., 56 (1991) 4543–4545.CrossRefGoogle Scholar
  8. [8]
    Thrash, T.P., Cagle, D.W., Alford, J.M., Wright, K., Ehrhardt, G.J, Mirzadeh, S., Wilson, L.J.: Chem. Phys. Lett., 308 (1999) 329–336.CrossRefGoogle Scholar
  9. [9]
    Lawrence, K.L.S, Ehrhardt, G.J., Cagle, D.W., Thrash, T.P., Wilson, L.J.: Fullerenes: Recent Advances in the Chemistry and Physics of Fullerenes and Related Materials, K. Kadish and R.S. Ruoff (Eds.), Vol. 2, 1995, Electrochemical Society, pp. 66–71.Google Scholar
  10. [10]
    Volkert, W.A., Goeckeler, W.F., Ehrhardt, G.J., Ketring, A.R.:. J. Nucl. Med., 1 (1991) 174–185.Google Scholar
  11. [11]
    Cagle, D.W., Kennel, S.J., Mirzadeh, S., Alford, J.M., Wilson, L.J.: Proc. Natl. Acad. Sci. USA, 96 (1999) 5182.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2000

Authors and Affiliations

  • G. J. Ehrhardt
    • 1
  • L. J. Wilson
    • 1
  1. 1.USA

Personalised recommendations